Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Short-Course Chemotherapy for Poor-Risk Lymphoma and B-ALL
NCT00002471Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 1990
- Primary completion
- Jan 2003
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, thiotepa, vincristine, daunorubicin, dexamethasone in B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 1990; status: completed.
02
Drugs
cyclophosphamidethiotepavincristinedaunorubicindexamethasone
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00002471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002471.